Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)
A Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimura™ (Complement C5 Inhibitor) Compared to Sham in Subjects With Autosomal Recessive Stargardt Disease
Sponsor: Astellas Pharma Global Development, Inc.
A observational or N/A phase clinical study on Stargardt's Macular Dystrophy, this trial is completed. The trial is conducted by Astellas Pharma Global Development, Inc. and has accumulated 42 data snapshots since 2018. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
42 versions recorded-
Apr 16, 2026 — Present [daily]
Completed
Phase: PHASE2 → None
-
Mar 2026 — Apr 2026 [monthly]
Completed PHASE2
-
Sep 2025 — Mar 2026 [monthly]
Completed PHASE2
-
Jun 2025 — Sep 2025 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jan 2025 — Jun 2025 [monthly]
Active Not Recruiting PHASE2
▶ Show 37 earlier versions
-
Nov 2024 — Jan 2025 [monthly]
Active Not Recruiting PHASE2
-
Sep 2024 — Nov 2024 [monthly]
Active Not Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE2
-
Jun 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
-
Mar 2024 — Jun 2024 [monthly]
Active Not Recruiting PHASE2
-
Nov 2023 — Mar 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Oct 2023 — Nov 2023 [monthly]
Recruiting PHASE2
-
Jun 2023 — Oct 2023 [monthly]
Recruiting PHASE2
-
Apr 2023 — Jun 2023 [monthly]
Recruiting PHASE2
-
Sep 2022 — Apr 2023 [monthly]
Recruiting PHASE2
-
Oct 2021 — Sep 2022 [monthly]
Recruiting PHASE2
-
Sep 2021 — Oct 2021 [monthly]
Recruiting PHASE2
-
Jun 2021 — Sep 2021 [monthly]
Recruiting PHASE2
-
Feb 2021 — Jun 2021 [monthly]
Recruiting PHASE2
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE2
-
Oct 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Sep 2020 — Oct 2020 [monthly]
Recruiting PHASE2
Status: Active Not Recruiting → Recruiting
-
Jun 2020 — Sep 2020 [monthly]
Active Not Recruiting PHASE2
-
Feb 2020 — Jun 2020 [monthly]
Active Not Recruiting PHASE2
-
Dec 2019 — Feb 2020 [monthly]
Active Not Recruiting PHASE2
-
Apr 2019 — Dec 2019 [monthly]
Active Not Recruiting PHASE2
-
Mar 2019 — Apr 2019 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Feb 2019 — Mar 2019 [monthly]
Recruiting PHASE2
-
Jan 2019 — Feb 2019 [monthly]
Recruiting PHASE2
-
Dec 2018 — Jan 2019 [monthly]
Recruiting PHASE2
-
Nov 2018 — Dec 2018 [monthly]
Recruiting PHASE2
-
Oct 2018 — Nov 2018 [monthly]
Recruiting PHASE2
-
Sep 2018 — Oct 2018 [monthly]
Recruiting PHASE2
-
Aug 2018 — Sep 2018 [monthly]
Recruiting PHASE2
-
Jul 2018 — Aug 2018 [monthly]
Recruiting PHASE2
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE2
-
May 2018 — Jun 2018 [monthly]
Recruiting PHASE2
-
Apr 2018 — May 2018 [monthly]
Recruiting PHASE2
-
Mar 2018 — Apr 2018 [monthly]
Recruiting PHASE2
-
Feb 2018 — Mar 2018 [monthly]
Recruiting PHASE2
-
Jan 2018 — Feb 2018 [monthly]
Recruiting PHASE2
-
Dec 2017 — Jan 2018 [monthly]
Recruiting PHASE2
First recorded
Eligibility Summary
The purpose of this study is to evaluate the safety and efficacy of avacincaptad pegol intravitreal injection compared to Sham in participants with autosomal recessive Stargardt disease 1 (STGD1).
Contact Information
- Astellas Pharma Global Development, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Ann Arbor, United States , Austin, United States , Baltimore, United States , Barcelona, Spain , Bloomfield, United States , Bologna, Italy , Bonn, Germany , Boston, United States , Budapest, Hungary , Budapest, Hungary and 31 more locations